IntellBio Receives 100 million Yuan in Strategic Investment

On August 29,  IntellBio, a biotechnology company, received 100 million yuan in strategic investment from Jinhe Capital and Cathay Capital.

IntellBio will use the funding to expand the product line, improve technology, and submit application to CFDA.

Founded in 2013, IntellBio is a national high-tech enterprise with 50 million yuan of registered capital. IntellBio’s business includes development, production, sales and service of life science analytical instruments.

IntellBio has established R&D centers in Boston, Beijing, Qingdao, Nanjing, Hangzhou and other places in the United States and cooperated with China Agricultural University, Chinese Academy of Sciences and other scientific research institutions to establish joint laboratories. The company has undertaken a number of national science and technology innovation projects.

Since establishment, IntellBio has invested more than 50 million yuan in research and development. The company has two technology platforms for QuanTOF and QuanPLEX. The QuanTOF was identified by the committee of Academician of Chinese Academy of Sciences (CAS) as "the overall performance reaches the international leading level".

Based on two core technology platform, IntellBio developed a series of products, including SNP genotyping mass spectrometry system, mass spectrometry imaging system, respiratory pathogen detection system, avian influenza virus detection system, and transgenic testing system. The application of IntellBio covers clinical treatment, inspection, food safety, disease control, and other fields.

Founded in 2017, Jinhe Capital is an investment company in Guangzhou.

Founded in 2007, Cathay Capital is an investment company in Shanghai, focusing on the field of medical devices, animal health care, agricultural products processing, and software engineering.